PMC:3724972 / 25487-25902 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3724972","sourcedb":"PMC","sourceid":"3724972","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3724972","text":"Doxazosin\nThe selective alpha(1)-adrenergic receptor antagonist, doxazosin has been shown to decrease plasma ACTH and inhibit proliferation in human and murine pituitary tumor cells, and may represent a potentially useful treatment option in pituitary adenomas [73]. However, there is currently no clinical experience with doxazosin, and more data are required before any such treatment strategy could be advocated.","divisions":[{"label":"title","span":{"begin":0,"end":9}}],"tracks":[{"project":"2_test","denotations":[{"id":"23673515-16020484-63233674","span":{"begin":262,"end":264},"obj":"16020484"}],"attributes":[{"subj":"23673515-16020484-63233674","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93e9ec","default":true}]}]}}